

Letaplimab

Cat. No.:	HY-P99700
CAS No.:	2283356-07-8
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRP α . Letaplimab enhances tumor cell phagocytosis^[1].

REFERENCES

[1]. Miao Miao, et al. A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome. MYELODYSPLASTIC SYNDROMES-CLINICAL AND EPIDEMIOLOGICAL NOVEMBER 15, 2022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA